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Abstract
Summary We identified factors associated with oral
bisphosphonate treatment in 50+-year-old female patients
with a first fracture, osteoporosis diagnosis, or BMD ≤−2.5
in the Geisinger Health System electronic health record
database. Treatment was positively associated with age, oral
corticosteroids, and smoking, and negatively associated
with body mass index and bone mineral density scores.
Introduction To identify factors associated with oral
bisphosphonate treatment in patients with an indicator for
post-menopausal osteoporosis.
Methods Females age 50+ years with a first fracture,
osteoporosis diagnosis, or bone mineral density (BMD)
≤−2.5 (index date) were identified in the Geisinger Health
System electronic health record database. Treatment was
defined as an oral bisphosphonate prescription order
(risedronate sodium, ibandronate sodium, or alendronate)
≤90 days post-index date. Treatment rates were assessed
and a multivariate logistic model was used to identify
predictors of treatment separately for patients with fracture
(FRAC) and with diagnosis or low BMD (ICD-9-BMD).
Results The FRAC group had 2,003 female patients with a
mean (SD) age of 69.0 (±11.3) years and the ICD-9-BMD
group had 12,976 female patients with a mean (SD) age of
66.9 (±10.0) years. Within 90 days of the index date of
fracture, diagnosis, or low BMD score, 188 (9.4%) patients
in the FRAC group and 5,395 (41.6%) in the ICD-9-BMD
group received treatment. Treatment was positively associ-
ated with age and oral corticosteroids and negatively
associated with body mass index and subsequent BMD in
both groups. Smoking currently was positively associated
with treatment in the ICD-9-BMD group.
Conclusion Certain patient characteristics are predictors of
physicians prescribing oral bisphosphonates. However,
many patients remain untreated.
Keywords Bonemineraldensity.Fracture.Oral
bisphosphonate.Osteoporosis.Realworlddata
Introduction
Osteoporosis is a skeletal disorder characterized by low bone
mineral density (BMD) and a disruption of normal bone
architecture.Itisamajorriskfactorfor fracture,whichleads to
substantial morbidity and mortality [1]. Osteoporotic fractures
are common; it is estimated that one half of all post-
menopausal women will have a fracture in her lifetime [2].
Hip fractures reduce life expectancy, by 25% in one study
[3], and are associated with a substantial decrease in quality
of life [4]. The estimated societal cost of osteoporotic
fractures in the USA was $13.8 billion in 1995 [5].
Osteoporosis will likely become increasingly burdensome as
the proportion of the US population that is elderly increases.
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DOI 10.1007/s00198-009-1079-7The aim of treatment of established osteoporosis is to
maintain and, ideally, to restore bone strength with the
ultimate goal of preventing fractures. There are currently a
number of FDA-approved agents for the treatment of
osteoporosis including bisphosphonates (e.g., alendronate,
ibandronate, or risedronate), raloxifene, teriparatide, and
calcitonin. Estrogen replacement therapy is indicated for the
prevention of osteoporosis. All of these agents have been
shown to increase BMD and several have shown efficacy in
fracture risk reduction [6].
Thus, drug therapy is a key therapeutic component in
preventing osteoporosis fractures in patients at risk for
fracture. However, it is estimated that only 36% of
women with post-menopausal osteoporosis are treated
with any agent for the prevention or treatment of
osteoporosis, and specifically, only 16% were treated
with bisphosphonate or calcitonin [7]. A number of
studies have examined predictors of treatment to help
understand what factors clinicians are weighting most
heavily in determining whether to treat osteoporotic
patients. Ideally, predictors of treatment should mirror
predictors of fracture. Surprisingly, many of these studies
have found that this is not necessarily the case. Increased
age, oral corticosteroid usage, and smoking status are all
risk factors for osteoporosis and fracture [8] but have often
been found to have either a negative association or no
association with treatment administration [9–20]. Yet
several studies have found that either older patients are
less likely to get treatment [12, 18, 22]o rt h e r ei sn o
association between age and treatment [20, 23].Low
T-scores on BMD tests are strong predictors of fracture
but are often not available for researchers. In this study,
we distinguish osteoporotic patients based on having a
fracture or having a low BMD T-score or a diagnosis code
for osteoporosis. Few studies have examined factors
associated with treatment in patients with these specific
characteristics [11, 21]. As noted, the risk of fracture
increases with age.
The objective of this study was to identify predictors
of osteoporosis treatment. This was done separately for
two subgroups of osteoporosis patients: (1) those with a
fracture (FRAC group) (2) and those with either an
International Classification of Diseases (ICD)-9 code for
osteoporosis and/or a low (≤−2.5) T-score from a BMD
test (ICD-9-BMD group). Potential predictors were
included based on their association with bone health
and fall risk. The evaluated predictors included weight,
body mass index (BMI), smoking status, excessive
alcohol consumption, a history of previous fractures,
BMD T-score, comorbid conditions, and drug exposures.
In this study, we focused specifically on prescribing for
oral bisphosphonates (risedronate, alendronate, and
ibandronate). Bisphosphonates are a commonly used
class of prescription drugs for the treatment of osteo-
porosis [24], and in patients with low bone density,
bisphosphonate have been shown to reduce fracture risk
by 40–50% [25].
Methods
Study design
This study utilized a retrospective cohort design to evaluate
the association between observable clinical characteristics
and drug treatment for osteoporosis.
Data
We used data from the Geisinger Health System (GHS)
from January 1, 2000–June 30, 2007. GHS was founded
in 1915 and is a physician-led organization comprised of
650 plus physicians, 75 medical and surgical specialties,
and 42 pediatric medical and surgical subspecialties.
GHS, which also has one of the largest not for profit
rural HMOs in the USA, has three existing hospitals
(primary to quaternary care) and 41 community practice
offices. The GHS service area is limited to the state
Pennsylvania. The core of the data originates from an
electronic medical record (EMR) infrastructure that con-
tains longitudinal clinical patient data including lab results
for nearly three million patients from 1996 to 2006. A
unique feature of this dataset is the availability of
diagnostic testing results. For the present study, we
utilized results from BMD tests. The data was obtained
through MedMining (a Geisinger Health System Busi-
ness), which has developed a proprietary, Health Infor-
mation Portability and Accountability Act compliant
research database based on the GHS data.
Study population
The cohort population was selected based on specific
criteria. Female patients age 50 and older were selected
for inclusion into the study if they had at least one of
three separate identifiers for osteoporosis from January 1,
2000 through June 30, 2007: (1) ICD-9 codes for
osteoporosis (733.0, 733.00, 733.01, 733.03, 733.09);
(2) a BMD T-score of −2 . 5o rl e s s ;o r( 3 )af r a c t u r eo n
or after age 50 with no fracture in the 6 months prior.
Locations for fractures were identified by ICD-9 codes
(Table 1) for the clavicle, hip, humerus, pelvis, leg, wrist,
and spine. The date of osteoporosis identification was
designated as the patient’s index date. Patients were
excluded if they were not continuously active in the
database for 365+days prior to and 365+days after the
1428 Osteoporos Int (2010) 21:1427–1436index date, if they had both a fracture and at least one of
the other two osteoporosis identifiers, or if they had a
diagnosis for a condition known to impact bone density
and quality (i.e., Paget’s disease (ICD-9: 731.xx), second-
ary malignant neoplasm of bone and bone marrow (ICD-9:
198.5), and osteomylitis (ICD-9: 730.xx)).
Statistical analysis
Patients were stratified into two groups, FRAC and ICD-9-
BMD, based on reason for inclusion. Descriptive statistics,
including proportion of patients treated, were used to
characterize the baseline demographic and clinical charac-
teristics of patients in both groups.
A logistic regression was used to identify predictors of
osteoporosis treatment with an oral bisphosphonate (risedr-
onate, alendronate, or ibandronate). Patients were identified
as treated if they had a prescription for one of the three
drugs on the index date or up to 90 days post-index date.
Regressions were run separately for each of the two patient
groups. Independent variables included age at index date
(50–64, 65–74, and 75+), BMI (≤24 kg/m
2,2 5 –29 kg/m
2,
30–34 kg/m
2, and 35+ kg/m
2), smoking status, excessive
alcohol consumption, fall history, insurance status (Medi-
care, private insurance, or no insurance), presence of an
order for a BMD test, and BMD T-score. The value for the
BMD T-score variable was the test result for the hip, if
available. If the hip T-score was not available, a spine test
result was used, and if neither a hip or spine result was
available, a forearm score was used. Values for the BMD
T-score variable included test results within the first 90 days
after the index date and was dichotomized based on
whether the value was greater than or less than or equal
to −2.5. Therefore, patients in the FRAC group, who by
definition did not have a T-score ≤−2.5 on the index date,
may still have a value for this variable below this threshold
if it was measured in the first 90 days post-index.
Furthermore, while it was not possible to link the cause of
the fracture for patients in the FRAC group to a specific
fall, if the fracture was the result of a fall, that fall would be
captured by the fall history variable. Also included were
diagnoses of comorbidities associated with bone health
such as aortic atherosclerosis, diabetes, thyroid disease, and
malnutrition. Indicators for the use of drugs over the study
period whose exposures are associated with fracture risk
were also included (e.g., chemotherapy, oral corticosteroids,
thyroid replacement therapy, and furosemide therapy).
Finally, a Charlson Comorbidity Index (CCI) score was
calculated for each patient based on comorbidities docu-
mented on or one year prior to their index date [26].
Initially, a forward selection process was undertaken by
running univariate regressions with each independent
variable. Variables whose coefficients had p values of
≤0.10 were chosen to be included in the full multivariate
regression. As a sensitivity analysis, calculations for
proportion of treated patients as well as regression models
were repeated using post-index date windows for defining
treatment of 180 and 365 days.
All statistical tests were performed at a 0.05 significance
level using Stata SE v. 9 (StataCorp, College Station,
Texas) and SAS v. 9 (Cary, NC.)
Results
Figure 1 is a Venn diagram depicting the portion of patients
with each of the three osteoporosis identifiers. The FRAC
group consisted of 2,003 females and the ICD-9-BMD
group was made up of 12,976 females. A total of 260
Table 1 Fragility fracture (Inclusion and Outcome Criteria)
Fracture site ICD-9-CM
1. Clavicle (closed) Closed 810.0x
2. Hip (closed) Pathologic 733.14
Transcervical 820.0x
Pertrochanteric 820.2x
Unspecified 820.8x
3. Humerus (closed) Pathologic 733.11
Upper end 812.0x
Shaft/unspecified 812.2x
Lower end 812.4x
4. Pelvis (closed) Acetabulum 808.0x
Pubis 808.2x
Other specified 808.4x
Unspecified 808.8x
5. Leg
Femur (closed) Pathologic 733.15
Shaft/unspecified 821.0x
Lower end 821.2x
Tibia/Fibula (closed) Pathologic 733.16
Upper end 823.0x
Shaft 823.2x
Unspecified 823.8x
6. Wrist (closed) Pathologic 733.12
Forearm upper end 813.0x
Shaft 813.2x
Lower end 813.4x
Unspecified 813.8x
7. Spine/vertebral (closed) Pathologic 733.13
Cervical, closed 805.0x
Dorsal, closed 805.2x
Lumbar, closed 805.4x
Unspecified, closed 805.8x
Osteoporos Int (2010) 21:1427–1436 1429patients, depicted in shaded regions in the figure, had both a
fracture and either a low BMD T-score or an ICD-9 code
for osteoporosis. These patients are included in Fig. 1 for
illustrative purposes but were excluded from the analysis in
order to isolate the two patient groups.
The mean age was 69.0 (SD±11.3) in the FRAC group
and 66.9 (SD±10.0) in the ICD-9-BMD group (Table 2). A
higher proportion of patients in the ICD-9-BMD group had
a BMD ordered at any point in the study period compared
to patients in the FRAC group (62.5% vs. 16.9%) and had
lower average T-scores for each of the three sites (hip, −1
[SD±1.1] vs. −0.7 [SD±1.2]; spine, −1.3 [SD±1.0]
vs. −0.8 [SD±1.5]; forearm, −1.5 [SD±1] vs. −1.2
[SD±1.1]). In both patient groups, most patients either
had never smoked (ICD-9-BMD, 60.3%; FRAC, 58.9%) or
were former smokers (ICD-9-BMD, 25.1%; FRAC,
58.9%). Most of the patients in the FRAC group had a
CCI ≥3 (63%), 16.3% were taking an oral corticosteroid,
and 2.5% had a diagnosis for rheumatoid arthritis. In the
ICD-9-BMD group, 46% of the patients had a CCI ≥3,
14.4% were taking an oral corticosteroid, and 4.4% had a
diagnosis of rheumatoid arthritis.
Only 188 (9.4%) of the patients in the FRAC group were
prescribed treatment in the first 90 days post-index date,
while 5,395 (41.6%) patients in the ICD-9-BMD group
were treated during this same time period (Table 3).
Treatment was prescribed for 13.4% and 18.5% of FRAC
patients in the 180 days and 365 days following the index
date, respectively. For the ICD-9-BMD patients, 45.9% had
been prescribed treatment within 180 days while 49.3% had
been prescribed treatment within 365 days.
In Table 4, results from the logistic regressions are
presented for patients in the FRAC group. Baseline results
for which treatment was defined as a prescription in the first
90 days following fracture are presented along with
alternative treatment definitions of 180 and 365 days.
Individuals between the ages of 65 and 74 were signifi-
cantly more likely to get treatment (OR=1.77, p=0.009)
compared with patients between 50 and 64. A low BMD
T-score (≤−2.5) after fracture date was significantly
associated with increased likelihood of receiving treatment
(OR=4.90, p<0.001). Obese patients were less likely to
receive treatment than underweight or normal weight
patients (OR=0.53, p=0.03), and those taking an oral
corticosteroid were more likely to receive treatment
(OR=1.67, p=0.01). The effects of covariates on the
likelihood of bisphosphonate treatment were similar using
treatment windows of 180 and 365 days post-index date;
however, more odds ratios reached statistical significance
as the number of treated patients increased.
Results from logistic regressions for patients in the
ICD-9-BMD are presented in Table 5. Treatment receipt
was positively associated with age, with patients between
the ages of 65 and 74 (OR=1.18, p<0.001) and 75 and
older (OR=1.57, p<0.001) significantly more likely to
receive treatment compared with patients between 50 and
64. A low BMD T-score (≤−2.5) was significantly
associated with an increased likelihood of receiving
treatment (OR=1.32, p=0.002). Patients who used to
smoke (OR=0.76, p<0.001) or who never smoked
(OR=0.72, p<0.001) were significantly less likely to
receive treatment than those who currently smoke. BMI
was negatively associated with treatment. Overweight
(OR=0.81, p<0.001), obese (OR=0.54, p<0.001), and
very obese (OR=0.46, p<0.001) patients were less likely
to receive treatment than those who were underweight or
normal weight. Patients with higher CCI (OR=0.96,
p<0.001) were less likely to receive treatment, while
t h o s et a k i n ga no r a lc o r t i c o s t e r o i d( O R = 1 . 3 4 ,p<0.001)
and those with rheumatoid arthritis (OR=1.40, p<0.001)
were more likely to receive treatment. Results were similar
using treatment windows of 180 and 365 days.
Discussion
The purpose of this study was to quantify how fracture
risk factors are associated with physicians prescribing
bisphosphonate treatment in women with post-
menopausal osteoporosis. The treatment rate was low,
especially in the FRAC group, with merely 9.4% having
a prescription order for an oral bisphosphonate in the
first 90 days following a fracture and only 18.5%
having such a prescription order if the follow-up period
is extended to 1 year. This result is similar to those
found in other studies where treatment rates have
BMD t-score < -2.5 
ICD-9 Code 
n = 11,414 
(74.9%) 
n = 2,003 
(13.1%) 
Fracture 
n = 241 
(1.6%) 
n = 5 
(0.03%) 
n = 14 
(0.09%) 
n = 341 
(2.2%) 
n = 1,221 
(8.0%) 
Total n = 15,239
Note: Bone Mineral Density (BMD); International Classification of Diseases – 9 (ICD-9)  Shaded patient counts
were excluded from the final analysis.
Fig. 1 Venn diagram showing portion of patients with each
osteoporosis identifier. Bone Mineral Density (BMD); International
Classification of Diseases 9 (ICD-9) Shaded patient counts were
excluded from the final analysis
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Fracture (n=2003) Low BMD or ICD-9 (n=12,976)
n/mean % or SD n/mean % or SD
Mean age (SD) 69.0 11.3 66.9 10.0
50–64 774 38.6 5,582 43.0
65–74 519 25.9 4,156 32.0
75+ 710 35.4 3,238 25.0
Race (n,% )
White 1,980 98.9 12,819 98.8
Black 6 0.3 38 0.3
Hispanic 5 0.2 32 0.2
Other 9 0.4 75 0.6
Unknown 3 0.1 12 0.1
Mean baseline BMD T-score (SD)
Forearm −1.2 1.1 −1.5 1.0
Hip −0.7 1.2 −1 1.1
Spine −0.8 1.5 −1.3 1.4
BMD T-score orders (n, %) 339 16.9 8,114 62.5
BMD T-score (n,% )
≤−2.5 26 1.3 560 4.3
>−2.5 to ≤−1.0 115 5.7 3,581 27.6
≥−1.0 to ≤1.0 156 7.8 3,283 25.3
≥1.0 25 1.2 310 2.4
Missing 17 0.8 380 2.9
Unknown 1,664 83.1 4,862 37.5
Smoking
Current smoker 185 9.2 1,285 9.9
Former smoker 486 24.3 3,262 25.1
Never smoker 1,179 58.9 7,828 60.3
Missing 153 7.6 601 4.6
Baseline BMI
Under/normal weight 232 11.6 3,051 23.5
Over weight 363 18.1 3,312 25.5
Obese 402 20.1 2,790 21.5
Very obese 134 6.7 500 3.9
Missing 872 43.5 3,323 25.6
Insurance status (n,% )
Medicaid 835 41.7 4,931 38.0
Medicare 709 35.4 4,710 36.3
Commercial 419 20.9 3,190 24.6
Self-pay 40 2.0 145 1.1
Excessive alcohol consumption (n, %) 8 0.4 32 0.2
Mean Charlson Comorbidity Index (SD) 2.3 1.1 2.0 1.1
0 217 10.8 2,015 15.5
1 263 13.1 2,545 19.6
2 254 12.7 2,356 18.2
3+ 1,269 63.4 6,060 46.7
Oral corticosteroid (n, %) 327 16.3 1,870 14.4
Rheumatoid arthritis (n, %) 50 2.5 575 4.4
Fall history (n, %) 812 40.5 1,445 11.1
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during 1 year follow-up periods [7, 27–30]. The rate of
treatment within 90 days of diagnosis in the ICD-9-BMD
group was also low (41.6%), and remained low at 1 year
after diagnosis of osteoporosis (49.3%). These treatment
rates all fall short of the estimates based on National
Osteoporosis Foundation (NOF) guidelines [31]. Based on
these guidelines, an estimated 72% of white women ages
65 and above should receive pharmacologic treatment for
osteoporosis. Our findings are more consistent with the
World Health Organization fracture risk assessment tool
(FRAX™) guidelines which suggest that 23–46% of post-
menopausal women should be treated for osteoporosis
[32].
These results illustrate a potential gap in terms of clinical
perception of fracture risk in a patient or benefits of therapy
and treatment guidelines based on known fracture risk
factors. Clinical guidelines recommend treatment in post-
menopausal women with a BMD T-score of ≤−2.5 or a
prior fragility fracture. Other post-menopausal women, who
are candidates for treatment, are those with high fracture
risk based on a high probability of a fracture within 10 years
[31]. The FRAX™ model was developed to provide a
measure of fracture risk based on known fracture risk
factors with or without BMD scores [33]. These tools help
clinicians quantify risk and therefore help to target patients
for treatment. BMD tests are critical in making treatment
decisions. Treatment recommendations from the National
Center on Clinical Excellence recommend the use of
alendronate in patients with a fragility fracture only if they
have a T-score ≤−2.5 [34–36].
Thus, fracture risk factors should be drivers of treatment
and, therefore, should also be treatment predictors, which
was largely observed in this current study. Comparison of
these results to those of fracture from other studies reveals
some similarities but also many gaps. Low BMD T-scores,
smoking, and weight are all significant predictors of
fragility fracture which are shown here to be strongly
associated with treatment. However, fall history, excessive
alcohol consumption, comorbid conditions such as diabe-
tes, thyroid disease, aortic atherosclerosis, and malnutrition,
and drug exposures such as chemotherapy and thyroid
replacement therapy have all been shown to be associated
with fractures, but were not significant predictors of
initiation of treatment in this study.
Several of our findings are substantially different from
those found in earlier studies though consistent with what we
would expect. Earlier studies have reported either no
association between age and osteoporosis treatment or that
treatment is negatively associated with age [12, 18, 20, 22,
23]. That age is positively associated with treatment in our
study, while different from previous studies, makes clinical
sense given the strong association of age and osteoporosis
and fracture risk [15, 17]. Many other studies have also
failed to find as association between oral steroid use and
osteoporosis treatment [23, 37–39]. Again, our findings
Table 2 (continued)
Fracture (n=2003) Low BMD or ICD-9 (n=12,976)
n/mean % or SD n/mean % or SD
Aortic atherosclerosis (n, %) 41 2.0 151 1.2
Chemotherapy (n, %) 669 33.4 4,400 33.9
Diabetes (n, %) 657 32.8 2,844 21.9
Thyroid replacement therapy (n, %) 524 26.2 3,329 25.7
Thyroid disease (n, %) 842 42.0 5,201 40.1
Furosemide therapy (n, %) 695 34.7 2,693 20.8
Malnutrition (n, %) 291 14.5 1,393 10.7
SD standard deviation, BMD bone mineral density, ICD-9 International Classification of Diseases 9, BMI body mass index
Number of days from index date Fracture (n=2,003) Low BMD or ICD-9 (n=12,976)
n % n %
90 days 188 9.4 5,395 41.6
180 days 268 13.4 5,954 45.9
365 days 371 18.5 6,395 49.3
Table 3 Frequency of patients
treated at 90, 180, and 365 days
after index date
BMD bone mineral density,
ICD-9 International Classifica-
tion of Diseases
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cians making prescription decisions based on known risk
factors. At least one other study found that women with
rheumatoid arthritis were less likely to receive treatment
[12]. Once more, in finding that patients with this disease are
more likely to receive treatment, our results are more
consistent with expectations. Finally, while smoking status
has not been a significant predictor of treatment in other
studies [9, 12], it is in ours.
We found that BMI was negatively associated with
treatment, while other studies have either found the same
result [23] or no significant association between BMI and
treatment [9, 11]. Our findings on BMD T-scores are
consistent with several other studies [9–11, 13, 14, 16, 19].
However, previous studies looking at the association
between BMD T-scores and treatment have used prospec-
tive data sources. This is the first study to find this result
using a retrospective database.
Our results, particularly the low prescribing rates,
suggest there is room for improvement in prescription
drug prescribing for patients with osteoporosis. Efforts to
raise clinician’s awareness and adoption of the treatment
guidelines put forth by the NOF could potentially help
reduce fracture rates in women with post-menopausal
osteoporosis.
Limitations
This study provides insight into predictors of post-
menopausal osteoporosis treatment in a real-world setting
by whether women had a prior fracture or a diagnosis or
a low BMD T-score as indicators of osteoporosis.
However, several limitations warrant mention. First, the
EMR data represents care delivered to study patients
within GHS; care delivered by non-GHS providers would
likely not be included in the data unless reported by the
patient and documented in the EMR, including prescrip-
tion orders. As a health system, data is more likely to be
comprehensive than an EMR that was located in a single
site of care, such as an office based EMR system. The
Number of days from index date for treatment definition
90 days 180 days 365 days
Odds ratio P value Odds ratio P value Odds ratio P value
Age
50–64 (ref)
65–74 1.764 0.009 1.784 0.002 1.780 <0.001
75+ 1.469 0.119 1.632 0.018 1.463 0.032
Race
White (ref)
Other 0.788 0.762 0.514 0.389 0.591 0.415
BMD T-score category
≤−2.5 4.900 <0.001 3.441 0.007 5.750 <0.001
>−2.5 (ref)
Unknown 0.128 <0.001 0.180 <0.001 0.295 <0.001
Smoking
Current smoker (ref)
Former smoker 0.798 0.474 0.882 0.644 1.031 0.898
Never smoker 0.930 0.799 0.954 0.852 1.059 0.795
Unknown 0.225 0.011 0.286 0.007 0.383 0.010
Baseline BMI
Under/normal weight (ref)
Over weight 0.804 0.428 0.774 0.274 0.802 0.274
Obese 0.532 0.031 0.584 0.027 0.462 <0.001
Very obese 0.545 0.146 0.465 0.035 0.301 <0.001
Missing 0.845 0.521 0.671 0.067 0.535 <0.001
Charlson Comorbidity Index 1.034 0.269 1.040 0.122 1.033 0.138
Oral corticosteroid 1.669 0.014 1.358 0.092 1.270 0.136
Rheumatoid arthritis 1.650 0.254 2.179 0.031 1.765 0.092
Table 4 Logistic regression for
osteoporosis treatment—patients
with fracture
BMI body mass index, BMD
bone mineral density
Osteoporos Int (2010) 21:1427–1436 1433disadvantage of using data from a single healthcare
system is that the prescribing patterns and, thus,
predictors of treatment may not reflect prescribing
patterns of other health systems or of US prescribers
overall. Similarly, included patents reside in a single
geographic region. Thus, caution must be made in
generalizing these findings to other populations or the
USA as a whole.
Second, while this study did not include fractures that
were most likely due to trauma, it is still not possible from
the data to ascertain if fractures were fragility related or
primarily the result of an injury. Thus, fracture as a criterion
for defining osteoporosis in this study may lack sensitivity
and may help to explain why treatment rates were low in
the fracture group.
Finally, there is debate about whether antiresorptive
treatment should be initiated immediately after fracture [40,
41]. One recent study showed that zoledronate did not
delay union of hip fracture [42]. However, another study
examining patients with a humerus fracture showed that
bisphosphonate use increased the risk of non-union be-
tween 3 and 12 months after the fracture [43]. This suggests
that providers may wait for fragility fractures to heal before
initiating bisphosphonate therapy. While most fractures
would be healed in 90 days, the sensitivity analyses of
180 and 365 days for the treatment window indicate that the
choice of a 90 day treatment window versus a longer
window did not impact predictors of treatment or overall
treatment rate.
Conclusion
In this study, we found that many patient characteristics that
indicate fracture risk were predictive of oral bisphosphonate
treatment in a cohort of females age 50 and older with at
least one indicator for osteoporosis. Many of these
associations have not been found in previous studies.
However, several other known risk factors for fracture and
osteoporosis were not found to be significant predictors of
Number of days from index date for treatment definition
90 days 180 days 365 days
Odds ratio P value Odds ratio P value Odds ratio P value
Age
50–64 (ref)
65–74 1.176 <0.001 1.197 <0.001 1.248 <0.001
75+ 1.565 <0.001 1.524 <0.001 1.514 <0.001
Race
White (ref)
Other 1.369 0.059 1.289 0.127 1.197 0.281
BMD T-score category
≤−2.5 1.322 0.002 1.533 <0.001 1.651 <0.001
>−2.5 (ref)
Unknown 0.579 <0.001 0.591 <0.001 0.618 <0.001
Smoking
Current smoker (ref)
Former smoker 0.758 <0.001 0.754 <0.001 0.761 <0.001
Never smoker 0.715 <0.001 0.715 <0.001 0.711 <0.001
Unknown 0.336 <0.001 0.345 <0.001 0.356 <0.001
Baseline BMI
Under/normal weight (ref)
Over weight 0.805 <0.001 0.779 <0.001 0.739 <0.001
Obese 0.538 <0.001 0.513 <0.001 0.473 <0.001
Very obese 0.462 <0.001 0.394 <0.001 0.357 <0.001
Missing 0.726 <0.001 0.710 <0.001 0.701 <0.001
Charlson Comorbidity Index 0.955 <0.001 0.963 <0.001 0.968 <0.001
Oral corticosteroid 1.338 <0.001 1.336 <0.001 1.309 <0.001
Rheumatoid arthritis 1.395 <0.001 1.512 <0.001 1.732 <0.001
Table 5 Logistic regression for
osteoporosis treatment—patients
with low BMD or ICD-9 code
BMI body mass index, BMD
bone mineral density, ICD-9
International Classification of
Diseases 9
1434 Osteoporos Int (2010) 21:1427–1436treatment, and the treatment rate for those with a prior
fracture was low overall. This suggests that while prescrib-
ing patterns may be more consistent with recommendations
than previously evidenced, there remains opportunity for
improvement in the use of drug treatment to help avoid
fractures in women with post-menopausal osteoporosis.
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